6IB Stoklara Genel Bakış Bir biyofarmasötik şirketi olan Innovent Biologics, Inc. Çin Halk Cumhuriyeti'nde onkoloji, oftalmoloji, otoimmün ve kardiyovasküler ve metabolik hastalıklar alanlarında monoklonal antikorlar ve diğer ilaç varlıklarını geliştirmekte ve ticarileştirmektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Innovent Biologics, Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Innovent Biologics Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$4.32 52 Haftanın En Yüksek Seviyesi HK$6.20 52 Haftanın En Düşük Seviyesi HK$3.40 Beta 0.24 1 Aylık Değişim -6.09% 3 Aylık Değişim -30.32% 1 Yıllık Değişim -6.90% 3 Yıllık Değişim 0.47% 5 Yıllık Değişim 38.46% Halka arzdan bu yana değişim 116.00%
Son Haberler & Güncellemeler Innovent Biologics, Inc. announced that it has received funding from Xuhui Science and Technology Venture Capital Jan 01
Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration Dec 20
Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024 Dec 09
Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List Nov 28
New major risk - Share price stability Nov 10
Forecast to breakeven in 2025 Oct 28 Daha fazla güncelleme görün Innovent Biologics, Inc. announced that it has received funding from Xuhui Science and Technology Venture Capital Jan 01
Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration Dec 20
Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024 Dec 09
Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List Nov 28
New major risk - Share price stability Nov 10
Forecast to breakeven in 2025 Oct 28
Co-Founder recently sold €9.5m worth of stock Oct 06
First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023) Sep 29
Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA Sep 26
Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress Sep 18
Forecast to breakeven in 2025 Sep 09
Innovent Biologics, Inc. Announces Change in Composition of Board Committees Aug 30
First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023) Aug 29
Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China Aug 22
The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert Aug 21
Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024 Aug 15
Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA) Aug 02
the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc Aug 01
Forecast to breakeven in 2025 Jul 29
Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions Jun 25
High number of new directors Jun 02
Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA May 29
Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311 May 23
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer May 08
Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022) Apr 30
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer Apr 30
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status Apr 03
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application Apr 02
Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024 Mar 21
Full year 2023 earnings released Mar 20
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024 Mar 07
Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer Mar 06
Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 01
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease Feb 20
Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee Feb 10
Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China Feb 07 Innovent Biologics, Inc. Announces Chief Financial Officer Changes Feb 05
Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints Jan 09
China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib Dec 19
Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications Dec 18
Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Dec 08
Forecast to breakeven in 2025 Dec 04
Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351 Nov 25
Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib Nov 23
Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care Nov 22
The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients Nov 18
Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity Oct 30
Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor) Sep 29
Now 20% undervalued Sep 26 Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion. Sep 20
New minor risk - Shareholder dilution Sep 19
First half 2023 earnings released: CN¥0.091 loss per share (vs CN¥0.65 loss in 1H 2022) Aug 23
National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo Aug 17
New major risk - Share price stability Aug 10
Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023 Aug 08 IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting Jun 12 Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting
Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC Jun 05
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Jun 03
Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint May 11
Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy May 10
No longer forecast to breakeven Apr 23
Full year 2022 earnings released Mar 29
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis Feb 16
Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy Feb 15
Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications Jan 19
Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Jan 10
Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib Jan 06
Forecast to breakeven in 2025 Dec 31 Innovent Biologics, Inc. Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353) Dec 05
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity Nov 15
Innovent Biologics, Inc. Releases Results of a Phase 3 Clinical Study of Tafolecimab(IBI306)in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022 Nov 07
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors Oct 31
Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine Oct 19
Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine Oct 17 Innovent Biologics, Inc. Announces China NMPA Approves CYRAMZA (ramucirumab) for Treatment in Patients with Hepatocellular Carcinoma
Innovent Biologics, Inc. Announces Second Interim Analysis Results of the Randomized, Double-Blinded, Multi-Center Phase 3 ORIENT-31 Study Sep 08
Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity Sep 07
Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity Sep 06
No longer forecast to breakeven Aug 27
First half 2022 earnings released: CN¥0.65 loss per share (vs CN¥0.81 loss in 1H 2021) Aug 26
Innovent Biologics, Inc. Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies Aug 24
Innovent Biologics, Inc. Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) Aug 18
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-Severe Plaque Psoriasis Met Primary Endpoint Aug 11
Innovent Biologics, Inc. Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema Aug 08
Innovent Biologics, Inc. announced that it expects to receive HKD 4.83336 billion in funding from Sanofi Foreign Participations B.V. Aug 05 Hissedar Getirileri 6IB DE Biotechs DE Pazar 7D 2.4% 4.0% 0.7% 1Y -6.9% -10.2% 8.4%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 6IB geçen yıl % -10.2 oranında getiri sağlayan German Biotechs sektörünü aştı.
Getiri vs Piyasa: 6IB geçen yıl % 8.4 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 6IB's price volatile compared to industry and market? 6IB volatility 6IB Average Weekly Movement 11.9% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: 6IB hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: 6IB 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Bir biyofarmasötik şirketi olan Innovent Biologics, Inc. Çin Halk Cumhuriyeti'nde onkoloji, oftalmoloji, otoimmün ve kardiyovasküler ve metabolik hastalıklar alanlarında monoklonal antikorlar ve diğer ilaç varlıklarını geliştirmekte ve ticarileştirmektedir. İnsan anti-PD-1 monoklonal antikoru olan Tyvyt; tamamen insan anti-VEGF monoklonal antikoru olan BYVASDA; rekombinant kimerik murin/insan anti-CD20 monoklonal antikoru olan HALPRYZA'yı sunmaktadır; Tamamen insan antiTNF-a monoklonal antikoru olan SULINNO; seçici bir FGFR inhibitörü olan Pemazyre; yeni bir BCR-ABL TK olan Olverembatinib; VEGF reseptör 2 antagonisti olan Cyramza ve seçici ve güçlü bir RET kinaz inhibitörü olan Retsevmo. Şirket ayrıca tam insan BCMA CAR T-hücre tedavisi olan IBI-326; oral PI3Kd inhibitörü olan IBI-376; KRASG12C inhibitörü olan IBI-351; susturma baskılayıcı 1/TRK tirozin kinaz inhibitörü olan IBI-344; CEACAM5'i hedefleyen bir ADC olan IBI-126'yı geliştirmektedir; IBI-306, yeni bir anti-proprotein konvertaz subtilisin/keksin tip 9 enzim monoklonal antikoru; IBI-362, bir glukagon benzeri peptid-1 reseptörü/glukagon reseptörü ikili agonisti; ve IBI-112, yeni bir uzun etkili anti-IL-23.
Daha fazla göster Innovent Biologics, Inc. Temel Bilgiler Özeti Innovent Biologics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 6IB temel i̇stati̇sti̇kler Piyasa değeri €7.29b Kazançlar(TTM ) -€171.05m Gelir(TTM ) €995.40m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 6IB gelir tablosu (TTM ) Gelir CN¥7.46b Gelir Maliyeti CN¥2.12b Brüt Kâr CN¥5.34b Diğer Giderler CN¥6.62b Kazançlar -CN¥1.28b
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/02 07:29 Gün Sonu Hisse Fiyatı 2025/01/02 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Innovent Biologics, Inc. 52 Bu analistlerden 29, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Linda Lu BOCI Research Ltd. Wai Chak Yuen BOCI Research Ltd. Bo Li BofA Global Research
Göster 49 daha fazla analist 
